Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.

被引：0
|
作者：
Dimopoulos, Meletios A.
Voorhees, Peter M.
Goldschmidt, Hartmut
Baker, Ross I.
Shi, Yingqi
Rousseau, Els
Dennis, Robyn Monet
Carson, Robin L.
Rajkumar, S. Vincent
机构：
[1] Natl & Kapodistrian Univ Athens, Athens, Greece
[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[3] Univ Heidelberg Hosp, Internal Med 5, Heidelberg, Germany
[4] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[5] Murdoch Univ, Perth Blood Inst, Perth, Australia
[6] Janssen Res & Dev LLC, Spring House, PA USA
[7] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8075
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study
    Lonial, Sagar
    San-Miguel, Jesus F.
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Chari, Ajai
    Pineiro, Luis
    Wu, Kaida
    Wang, Jianping
    Doshi, Parul
    Schecter, Jordan
    Moreau, Philippe
    BLOOD, 2017, 130
  • [32] An open-label, dose-escalation phase lb study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).
    Nahi, Hareth
    Hellemans, Peter
    Masterson, Tara J.
    Clemens, Pamela L.
    Ahmadi, Tahamtan
    San Miguel, Jesus
    Mateos, Maria-Victoria
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
    San-Miguel, Jesus
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Liu, Kevin
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Luo, Man
    Farnsworth, Andrew
    Nahi, Hareth
    Chari, Ajai
    HAEMATOLOGICA, 2021, 106 (06) : 1725 - 1732
  • [34] MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
    Grosicki, Sebastian
    Crafoord, Jacob
    Koh, Youngil
    White, Darrel
    Mellqvist, Ulf-Henrik
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Pruchniewski, Lukasz
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
    Sonneveld, Pieter
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    Ukropec, Jon
    Smith, Elena
    Houkes, Nienke
    Schecter, Jordan Mark
    Kastritis, Efstathios
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study
    Nahi, Hareth
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Bandyopadhyay, Nibedita
    Hellemans, Peter
    Tromp, Brenda
    Nnane, Ivo
    Zemlickis, Donna
    Farnsworth, Andrew
    Chari, Ajai
    BLOOD, 2021, 138
  • [37] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
    Dimopoulos, Meletios
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David
    Weisel, Katja
    Yang, Hui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Usmani, Saad Z.
    LANCET, 2020, 396 (10245): : 186 - 197
  • [38] Original Research Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study*
    Mateos, Maria-Victoria
    Hernandez, Miguel-Teodoro
    Salvador, Carlos
    de la Rubia, Javier
    de Arriba, Felipe
    Lopez-Corral, Lucia
    Rosinol, Laura
    Paiva, Bruno
    Palomera, Luis
    Bargay, Joan
    Oriol, Albert
    Prosper, Felipe
    Lopez, Javier
    Arguinano, Jose-Maria
    Blade, Joan
    Lahuerta, Juan-Jose
    San-Miguel, Jesus
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : 243 - 250
  • [39] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Bahlis, Nizar J.
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Ukropec, Jon
    Qi, Ming
    San-Miguel, Jesus
    LEUKEMIA, 2020, 34 (07) : 1875 - 1884
  • [40] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Nizar J. Bahlis
    Meletios A. Dimopoulos
    Darrell J. White
    Lotfi Benboubker
    Gordon Cook
    Merav Leiba
    P. Joy Ho
    Kihyun Kim
    Naoki Takezako
    Philippe Moreau
    Jonathan L. Kaufman
    Maria Krevvata
    Christopher Chiu
    Xiang Qin
    Linda Okonkwo
    Sonali Trivedi
    Jon Ukropec
    Ming Qi
    Jesus San-Miguel
    Leukemia, 2020, 34 : 1875 - 1884
12345